S114 protects certain 340B healthcare providers from being treated differently by insurers, pharmacy benefit managers, drug manufacturers, or other payors because they participate in the federal 340B drug-discount program. It bars those entities from discriminating against 340B providers in the way prescription-drug benefits or reimbursements are handled.
The Rhode Island State House of Representatives passed S114 on June 20, 2025 by a vote of 58 to 8. We have assigned pluses to the nays because states should not support any programs that lack authorization under Article I, Section 8 of the U.S. Constitution. By forcing private drug manufacturers to comply with mandates that interfere with their freedom to contract, protected under Article I, Section 10, this bill violates constitutional safeguards, undermines federalism, and erodes free-market principles. Rather than protecting liberty, S114 entrenches an unconstitutional federal welfare program and expands government interference in healthcare.
